CRISPR-Cas9–based target validation for p53-reactivating model compounds
Authors:
Open Access
- 23 November 2015
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 12 (1) , 22-28
Abstract
CRISPR-Cas9 based target validation revealed that the sensitivity of the p53-reactivating compound RITA is independent of functional p53 and is reliant on the regulation of the DNA damage-activated Fanconi anemia pathway. Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9–based target validation in lung and colorectal cancer that the activity of nutlin, which blocks the p53-binding pocket of Mdm2, strictly depends on functional p53. In contrast, sensitivity to the drug RITA, which binds the Mdm2-interacting N terminus of p53, correlates with induction of DNA damage. Cells with primary or acquired RITA resistance display cross-resistance to DNA crosslinking compounds such as cisplatin and show increased DNA cross-link repair. Inhibition of FancD2 by RNA interference or pharmacological mTOR inhibitors restores RITA sensitivity. The therapeutic response to p53-reactivating compounds is therefore limited by compound-specific resistance mechanisms that can be resolved by CRISPR-Cas9–based target validation and should be considered when allocating patients to p53-reactivating treatments.Keywords
This publication has 52 references indexed in Scilit:
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cellsCell Death & Disease, 2011
- Chk2 mediates RITA-induced apoptosisCell Death & Differentiation, 2011
- Stage-specific sensitivity to p53 restoration during lung cancer progressionNature, 2010
- Rad18-mediated Translesion Synthesis of Bulky DNA Adducts Is Coupled to Activation of the Fanconi Anemia DNA Repair PathwayJournal of Biological Chemistry, 2010
- Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatmentProceedings of the National Academy of Sciences, 2009
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004